Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017 (2017), Article ID 7350251, 10 pages
https://doi.org/10.1155/2017/7350251
Research Article

Preventive Effects of a Chinese Herbal Formula, Shengjiang Xiexin Decoction, on Irinotecan-Induced Delayed-Onset Diarrhea in Rats

1School of Clinical Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China
2Department of Oncology of Integrative Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing 100029, China

Correspondence should be addressed to Liqun Jia; moc.liamtoh@aij-nuqil and Huangying Tan; ten.362@gniygnauhnat

Received 29 August 2016; Revised 13 December 2016; Accepted 18 December 2016; Published 12 January 2017

Academic Editor: Cheorl-Ho Kim

Copyright © 2017 Chao Deng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y.-Q. Liu, W.-Q. Li, S. L. Morris-Natschke et al., “Perspectives on biologically active camptothecin derivatives,” Medicinal Research Reviews, vol. 35, no. 4, pp. 753–789, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Van Cutsem, H.-J. Lenz, C.-H. Köhne et al., “Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer,” Journal of Clinical Oncology, vol. 33, no. 7, pp. 692–700, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Hayashi, J. Tsurutani, T. Satoh et al., “Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B,” Breast Cancer, vol. 20, no. 2, pp. 131–136, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Satouchi, Y. Kotani, T. Shibata et al., “Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509,” Journal of Clinical Oncology, vol. 32, no. 12, pp. 1262–1268, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Stein, W. Voigt, and K. Jordan, “Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management,” Therapeutic Advances in Medical Oncology, vol. 2, no. 1, pp. 51–63, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. P. M. Muehlbauer, D. Thorpe, A. Davis, R. Drabot, B. L. Rawlings, and E. Kiker, “Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy- and radiotherapy-induced diarrhea,” Clinical Journal of Oncology Nursing, vol. 13, no. 3, pp. 336–341, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. L. D. Hicks, J. L. Hyatt, S. Stoddard et al., “Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (irinotecan; CPT-11) toxicity,” Journal of Medicinal Chemistry, vol. 52, no. 12, pp. 3742–3752, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Rouits, V. Charasson, A. Pétain et al., “Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients,” British Journal of Cancer, vol. 99, no. 8, pp. 1239–1245, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Yamamoto, A. Kurita, T. Asahara et al., “Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats,” Oncology Reports, vol. 20, no. 4, pp. 727–730, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Sharma, P. Tobin, and S. J. Clarke, “Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea,” Lancet Oncology, vol. 6, no. 2, pp. 93–102, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. J. A. Maroun, L. B. Anthony, N. Blais et al., “Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea,” Current Oncology, vol. 14, no. 1, pp. 13–20, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. A. B. Benson III, J. A. Ajani, R. B. Catalano et al., “Recommended guidelines for the treatment of cancer treatment-induced diarrhea,” Journal of Clinical Oncology, vol. 22, no. 14, pp. 2918–2926, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Barbounis, G. Koumakis, M. Vassilomanolakis, M. Demiri, and A. P. Efremidis, “Control of irinotecan-induced diarrhea by octreotide after loperamide failure,” Supportive Care in Cancer, vol. 9, no. 4, pp. 258–260, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. P. M. Hoff, D. F. Saragiotto, C. H. Barrios et al., “Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial,” Journal of Clinical Oncology, vol. 32, no. 10, pp. 1006–1011, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Karthaus, H. Ballo, W. Abenhardt et al., “Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer,” Oncology, vol. 68, no. 4–6, pp. 326–332, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Takasuna, T. Hagiwara, K. Watanabe et al., “Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea,” Cancer Chemotherapy and Pharmacology, vol. 58, no. 4, pp. 494–503, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Mego, J. Chovanec, I. Vochyanova-Andrezalova et al., “Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study,” Complementary Therapies in Medicine, vol. 23, no. 3, pp. 356–362, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Xue, M. B. Sawyer, C. J. Field, L. A. Dieleman, D. Murray, and V. E. Baracos, “Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor,” Journal of Nutrition, vol. 138, no. 4, pp. 740–746, 2008. View at Google Scholar · View at Scopus
  19. S. Anami, K. Saegusa, M. Nishikata et al., “Effect of glutamine or alkaline ionized water on late diarrhea induced by irinotecan hydrochloride in Gunn rats,” Asian Journal of Pharmaceutical Sciences, vol. 4, no. 2, pp. 96–105, 2009. View at Google Scholar · View at Scopus
  20. G.-C. Sergio, G.-M. Félix, and J.-V. Luis, “Activated charcoal to prevent irinotecan-induced diarrhea in children,” Pediatric Blood & Cancer, vol. 51, no. 1, pp. 49–52, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Michael, M. Brittain, J. Nagai et al., “Phase II study of activated charcoal to prevent irinotecan-induced diarrhea,” Journal of Clinical Oncology, vol. 22, no. 21, pp. 4410–4417, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Mori, T. Kondo, Y. Kamiyama, Y. Kano, and K. Tominaga, “Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer,” Cancer Chemotherapy and Pharmacology, vol. 51, no. 5, pp. 403–406, 2003. View at Google Scholar · View at Scopus
  23. M. Chikakiyo, M. Shimada, T. Nakao et al., “Kampo medicine “Dai-kenchu-to” prevents CPT-11-induced small-intestinal injury in rats,” Surgery Today, vol. 42, no. 1, pp. 60–67, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Lam, S. Bussom, F. Guan et al., “Chemotherapy: the four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity,” Science Translational Medicine, vol. 2, no. 45, p. 45ra59, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Wang, L. Q. Jia, H. Y. Tan, L. Pan, L. L. Yu, and B. Deng, “Effect of Shengjiang Xiexin decoction on the repair of damaged rat intestinal mucosa after irinotecan chemotherapy,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 35, no. 10, pp. 1236–1243, 2015. View at Google Scholar
  26. H. Y. Deng, L. Q. Jia, L. Pan, and L. L. Yu, “Effect of ShengJiangXieXinTang on the intestinal mucosal immune barrier of rats receiving irinotecan,” Chinese Journal of Immunology, vol. 23, no. 7, pp. 620–622, 2007. View at Google Scholar
  27. O. C. Trifan, W. F. Durham, V. S. Salazar et al., “Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11,” Cancer Research, vol. 62, no. 20, pp. 5778–5784, 2002. View at Google Scholar · View at Scopus
  28. A. Kurita, S. Kado, N. Kaneda, M. Onoue, S. Hashimoto, and T. Yokokura, “Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats,” Cancer Chemotherapy and Pharmacology, vol. 46, no. 3, pp. 211–220, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. T. D. Schmittgen and K. J. Livak, “Analyzing real-time PCR data by the comparative CT method,” Nature Protocols, vol. 3, no. 6, pp. 1101–1108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Y. Shiau and G. W. Chang, “Effects of dietary fiber on fecal mucinase and β-glucuronidase activity in rats,” The Journal of Nutrition, vol. 113, no. 1, pp. 138–144, 1983. View at Google Scholar · View at Scopus
  31. S. Ohnishi and H. Takeda, “Herbal medicines for the treatment of cancer chemotherapy-induced side effects,” Frontiers in Pharmacology, vol. 6, article 14, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. J. M. Williams, C. A. Duckworth, A. J. M. Watson et al., “A mouse model of pathological small intestinal epithelial cell apoptosis and shedding induced by systemic administration of lipopolysaccharide,” Disease Models & Mechanisms, vol. 6, no. 6, pp. 1388–1399, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Mazumder, D. Plesea, and A. Almasan, “Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis,” Methods in Molecular Biology, vol. 414, pp. 13–21, 2007. View at Google Scholar · View at Scopus
  34. L. G. Van Der Flier and H. Clevers, “Stem cells, self-renewal, and differentiation in the intestinal epithelium,” Annual Review of Physiology, vol. 71, pp. 241–260, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. L. A. Chia and C. J. Kuo, “Chapter 7-the intestinal stem cell,” Progress in Molecular Biology and Translational Science, vol. 96, pp. 157–173, 2010. View at Publisher · View at Google Scholar
  36. F. Sipos and G. Muzes, “Injury-associated reacquiring of intestinal stem cell function,” World Journal of Gastroenterology, vol. 21, no. 7, pp. 2005–2010, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. T. M. Yeung, L. A. Chia, C. M. Kosinski, and C. J. Kuo, “Regulation of self-renewal and differentiation by the intestinal stem cell niche,” Cellular and Molecular Life Sciences, vol. 68, no. 15, pp. 2513–2523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. R. K. Montgomery and D. T. Breault, “Small intestinal stem cell markers,” Journal of Anatomy, vol. 213, no. 1, pp. 52–58, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Barker, J. H. Van Es, J. Kuipers et al., “Identification of stem cells in small intestine and colon by marker gene Lgr5,” Nature, vol. 449, no. 7165, pp. 1003–1007, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. P.-Y. Chang, X. Jin, Y.-Y. Jiang, L.-X. Wang, Y.-J. Liu, and J. Wang, “Mensenchymal stem cells can delay radiation-induced crypt death: impact on intestinal CD44+ fragments,” Cell and Tissue Research, vol. 364, no. 2, pp. 331–344, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Wang, D. Scoville, X. C. He et al., “Isolation and characterization of intestinal stem cells based on surface marker combinations and colony-formation assay,” Gastroenterology, vol. 145, no. 2, pp. 383.e21–395.e21, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. H. I. Swanson, “Drug metabolism by the host and gut microbiota: a partnership or rivalry?” Drug Metabolism and Disposition, vol. 43, no. 10, pp. 1499–1504, 2015. View at Google Scholar
  43. M. J. Kang, H. G. Kim, J. S. Kim et al., “The effect of gut microbiota on drug metabolism,” Expert Opinion on Drug Metabolism & Toxicology, vol. 9, no. 10, pp. 1295–1308, 2013. View at Publisher · View at Google Scholar
  44. A. M. Stringer, R. J. Gibson, R. M. Logan, J. M. Bowen, A. S. J. Yeoh, and D. M. K. Keefe, “Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhoea model in rats,” Cancer Biology & Therapy, vol. 7, no. 12, pp. 1919–1925, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Wang, M.-L. Wang, Y. Li, Y.-B. Zhou, and D.-S. Wang, “Clinical study on risk factor associated with gut flora change in patients with rectal cancer during perioperative period,” Zhonghua Wei Chang Wai Ke Za Zhi, vol. 15, no. 6, pp. 570–573, 2012. View at Google Scholar · View at Scopus
  46. A. Takakura, A. Kurita, T. Asahara et al., “Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat,” Oncology Letters, vol. 3, no. 3, pp. 520–524, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. B. D. Wallace, H. Wang, K. T. Lane et al., “Alleviating cancer drug toxicity by inhibiting a bacterial enzyme,” Science, vol. 330, no. 6005, pp. 831–835, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Taha, S. Sultan, H. A. Nuzar et al., “Synthesis and biological evaluation of novel N-arylidenequinoline-3-carbohydrazides as potent β-glucuronidase inhibitors,” Bioorganic and Medicinal Chemistry, vol. 24, no. 16, pp. 3696–3704, 2016. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Kong, T. Liu, X. Zhu et al., “Old drug new use—amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity,” Clinical Cancer Research, vol. 20, no. 13, pp. 3521–3530, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Ahmad, M. A. Hughes, L.-A. Yeh, and J. E. Scott, “Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors,” Journal of Biomolecular Screening, vol. 17, no. 7, pp. 957–965, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Narita, E. Nagai, H. Hagiwara, M. Aburada, T. Yokoi, and T. Kamataki, “Inhibition of β-glucuronidase by natural glucuronides of Kampo, medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate,” Xenobiotica, vol. 23, no. 1, pp. 5–10, 1993. View at Publisher · View at Google Scholar · View at Scopus
  52. D. Fujita, Y. Saito, T. Nakanishi, and I. Tamai, “Organic anion transporting polypeptide (OATP)2B1 contributes to gastrointestinal toxicity of anticancer drug SN-38, active metabolite of irinotecan hydrochloride,” Drug Metabolism and Disposition, vol. 44, no. 1, pp. 1–7, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Chen, C. Tao, Z. Liu et al., “A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome,” Phytotherapy Research, vol. 29, no. 11, pp. 1822–1827, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Chen, Z. Yu, Y. Li, J. Fichna, and M. Storr, “Effects of berberine in the gastrointestinal tract—a review of actions and therapeutic implications,” American Journal of Chinese Medicine, vol. 42, no. 5, pp. 1053–1070, 2014. View at Publisher · View at Google Scholar · View at Scopus